Instructions Erbisol Extra solution for injection ampoule 2 ml No. 10
Composition
Active ingredients: 1 ml of the drug contains: a complex of natural non-protein low-molecular organic compounds of non-hormonal origin, obtained from animal embryonic tissue, oligopeptides and glycopeptides (total 0.07-0.4 mg), nucleotides, amino acids.
excipients: 0.9% isotonic sodium chloride solution.
Dosage form
Solution for injection.
Main physicochemical properties: transparent or slightly opalescent colorless or light yellow liquid with a specific odor.
Pharmacotherapeutic group
Immunostimulants. ATX code L03A X.
Drugs affecting the digestive system and metabolism. ATX code A16A X.
Pharmacological properties
Pharmacodynamics.
The pharmacological activity of the drug is determined by the content of low-molecular biologically active peptides, which are characterized by immunomodulatory, reparative, antioxidant and antihypoxic effects.
The main immunomodulatory effect of the drug is manifested, first of all, through the effect on the macrophage link, which is responsible for the repair of damaged cells and the restoration of the functional activity of organs and tissues, as well as through NK cells (CD3-16+56+) and T-killers (CD3+16+56+), which are responsible for the destruction of damaged cells incapable of regeneration, or abnormal cells. At the same time, the drug has an immunocorrective effect and, in case of immune disorders, contributes to its normalization due to the activation of T-lymphocytes, Th1 helpers and T-killers, which is important for restoring the balance between cellular and humoral immunity.
The reparative properties of the drug are due to its immunomodulatory effect, which is manifested by an increase in the activity of macrophages (which cause the processes of repair of damaged cells and restoration of the functional activity of organs and tissues), as well as N- and T-killers, which are responsible for the destruction of damaged cells incapable of regeneration.
The antioxidant effect of the drug is manifested by inhibiting lipid peroxidation processes, increasing the activity of the glutathione-dependent antioxidant system of the blood, without changing the activity of microsomal oxidation enzymes and the content of cytochrome P450, as well as a membrane-stabilizing effect at the level of plasma membranes.
The drug realizes its antihypoxic properties by increasing oxygen consumption by tissues and improving tissue respiration as a result of increased electron transport in mitochondria, restoration of the proton gradient on their membranes, and shifting the oxyhemoglobin dissociation curve to the right, i.e., it enhances oxygen delivery to tissues.
The drug is non-toxic, devoid of cumulative toxicity, allergenic, teratogenic, mutagenic and carcinogenic properties.
Pharmacokinetics.
Not studied.
Indication
In complex therapy:
cardiovascular diseases: arterial hypertension, cardiomyopathy, myocarditis, ischemic heart disease, myocardial infarction, post-infarction cardiosclerosis, diffuse cardiosclerosis;
neurological diseases: cerebral atherosclerosis, stroke, neurological disorders associated with cerebral circulation disorders (after a stroke), polyneuritis of various genesis, demyelinating polyneuropathies, Parkinson's disease;
diseases of the gastrointestinal tract: acute and chronic hepatitis of various etiologies, hepatopathies, hepatoses, liver cirrhosis, pancreatitis, erosive gastroduodenitis, gastric and duodenal ulcers, nonspecific ulcerative colitis;
nonspecific diseases: nonspecific lung diseases (pneumonia, chronic bronchitis), metabolic dystrophies, angiopathy, to improve microcirculation, normalize vascular tone and blood supply, chronic renal failure, rheumatism, diffuse connective tissue diseases, systemic vasculitis, arthritis of various etiologies, deforming osteoarthritis, gout. ERBISOL® Extra is used in the complex treatment of people who have suffered from the effects of radiation exposure and environmental pollution, the drug has pronounced adaptive-corrective properties, increases the compensatory and protective functions of the body.
diabetes mellitus, thyroiditis, autoimmune insulin syndrome;
periodontitis and periodontosis;
in surgery and traumatology: obliterating diseases of the aorta and its branches of atherosclerotic genesis, obliterating endarteritis, diabetic macro- and microangiopathy, traumatic, postoperative and purulent wounds, trophic ulcers of various etiologies, bedsores, fractures (to accelerate the consolidation of bone fragments);
in allergology: allergic diseases, including bronchial asthma, atopic dermatitis and atopic rhinoconjunctivitis;
skin diseases: purulent skin diseases, dermatitis and toxicoderma, neurodermatoses, eczema, psoriasis;
in gerontology: functional insufficiency associated with age-related disorders of the liver, immune, nervous and cardiovascular systems. To increase physical activity and general vitality, potency.
Contraindication
Individual intolerance, hypersensitivity to any component of the drug.
Interaction with other medicinal products and other types of interactions
ERBISOL® Extra enhances the effect of antibacterial agents, exogenous interferons and at the same time reduces their toxic effect. For effective implementation of the directed immunomodulatory action, ERBISOL® Extra is not recommended to be prescribed with immunomodulators that stimulate humoral immunity. ERBISOL® Extra increases the sensitivity of receptors, therefore, when used together with hormonal drugs and biostimulants, their dosage should be controlled, reducing the dose if necessary.
Application features
With increased acidity of gastric juice, antisecretory and antacid drugs should be used.
With high blood pressure, as well as in the phase of exacerbation of the pathological process, the drug should be used with caution, reducing the dose. For the first 5 days, take 2 ml once in the morning, then 2 ml twice and further, according to the instructions.
In some cases, during the first 2-5 days of taking the drug, it may cause an exacerbation of the chronic inflammatory process, which in most cases is a stage of the treatment process.
Use during pregnancy or breastfeeding
Studies on the effectiveness of the drug ERBISOL® Extra during pregnancy or breastfeeding have not been conducted, therefore ERBISOL® Extra should not be prescribed during pregnancy or breastfeeding.
The ability to influence the reaction speed when driving or working with other mechanisms
The effect on the reaction rate when driving vehicles or using other mechanisms has not been studied. The ability of the drug ERBISOL® Extra to affect the reaction rate when driving vehicles or using other mechanisms is unlikely.
Method of administration and doses
The drug ERBISOL® Extra is used exclusively as part of complex therapy and is administered intramuscularly daily, 2-4 ml for 20-30 days, 2 times a day, preferably in the morning at 6-8 am, 1-2 hours before meals (when treating pancreatic diseases, at 9-11 am, 2-3 hours after meals), and in the evening, before bedtime, at 8-10 pm, 2-3 hours after meals.
In the complex therapy of neurological diseases (demyelinating polyneuropathies, Parkinson's disease), ERBISOL® Extra is administered intramuscularly 2 times a day: at 6-8 am and 8-10 pm, 2 ml for the first 3 days, the next 10-20 days are administered twice: at 6-8 am, 4 ml and at 8-10 pm, 2 ml, and then for 7-17 days, 2 ml twice.
In the complex treatment of neurological disorders associated with cerebral circulation disorders (after a stroke), in the post-infarction period, it is recommended to prescribe ERBISOL® Extra 7-10 days after the epicrisis intramuscularly, 2 ml daily in the morning for 20-30 days.
As part of the complex therapy of ischemic heart disease and peripheral circulatory disorders, the drug is prescribed intramuscularly daily, 2 ml twice a day for 20 days.
In the complex treatment of vascular obliterating diseases, the drug is administered intravenously drip 4 ml diluted in 250 ml of saline solution for 1-2 hours. The maintenance dose is provided by intramuscular injection of the drug twice daily, 2 ml in the morning and evening. The course of treatment is 10-15 days.
As part of complex therapy for nonspecific ulcerative colitis, ERBISOL® Extra is administered intramuscularly twice daily, 2 ml in the morning and evening for 20-30 days, and then daily 4 ml in the morning and 2 ml in the evening for 20-30 days, and then daily 2 ml in the morning and evening for 10-20 days.
In the complex therapy of wounds, periodontitis and periodontal diseases, the first 10 days are prescribed intramuscularly daily 2 times a day, 2 ml in the morning and evening, and the next 10 days, if necessary, 2 ml in the morning. In generalized periodontitis, applications and electrophoresis of ERBISOL® Extra from the anode (+) on the gums are additionally prescribed.
Comprehensive treatment of hepatosis, hepatitis, erosive-ulcerative lesions of the gastrointestinal tract, diffuse connective tissue diseases, traumatic lesions of tissues and organs, trophic ulcers of various etiologies, bedsores, to accelerate the consolidation of bone fragments, as well as to increase the compensatory and protective functions of the body, increase physical activity and general vitality, ERBISOL® Extra is prescribed intramuscularly daily, 2 ml twice a day in the morning and evening for 20 days, or 2 ml in the morning for the first 3 days, and for the next 10 days, 2 ml is administered twice in the morning and evening, then 2 ml in the morning for 7 days.
In the complex therapy of pancreatitis, during the first 10-20 days, ERBISOL® Extra is administered intramuscularly twice daily: 2 ml in the morning at 9-11 am and in the evening at 8-10 pm, and then for the next 10-20 days, 2 ml in the morning.
As part of complex therapy for diabetes mellitus, ERBISOL® Extra is administered intramuscularly twice daily for the first 20 days: 2 ml in the morning at 9-11 am and in the evening at 8-10 pm, and then 2 ml in the morning for the next 10 days. The course of treatment can be repeated 2-3 times a year.
Children.
The safety and effectiveness of the drug have not been studied in children, so it should not be prescribed to children.
Overdose
Short-term increased excitability is possible, which does not require specific therapy.
Side effects
Possible increases in blood pressure and body temperature. Possible hypersensitivity reactions.
Expiration date
5 years.
Do not use after the expiry date stated on the packaging.
Storage conditions
Store at a temperature of 4-12 ° C in a place inaccessible to children.
Opalescence may occur during storage.
Packaging
10 ampoules of 1 ml or 2 ml.
Vacation category
According to the recipe.
Producer
1. Private Enterprise "ERBIS Laboratory",
2. LLC "ERBIS"
Email: erbis@ukr.net
Website: www.erbisol.com.ua
Location of the manufacturer and its address of place of business. Ukraine, 02002, Kyiv, R. Okipnoi St., 10-B, office 92.
